There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...
The FDA's approval of zanubrutinib tablets reduces pill burden, potentially improving adherence, especially in older CLL patients, and solidifies its market leadership among Bruton tyrosine kinase ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results